New drug combo trial aims to boost fight against aggressive nasal cancer

NCT ID NCT04004871

Summary

This study tested whether a new three-drug chemotherapy combination (APF) given before standard radiation and chemo could better control advanced nasopharyngeal cancer. It involved 60 patients in China with newly diagnosed, locally advanced disease that had not spread. The goal was to see if this approach was safe and more effective at shrinking tumors and preventing cancer return.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NASOPHARYNGEAL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • The First Affiliated Hospital of Guangxi Medical University

    Nanning, Guangxi, 530021, China

Conditions

Explore the condition pages connected to this study.